Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 240Lung Neoplasms 59Neoplasms 57Stomach Neoplasms 56Head and Neck Neoplasms 56Squamous Cell Carcinoma of Head and Neck 47Parkinson Disease 4, Autosomal Dominant Lewy Body 44Neoplasm Metastasis 39Small Cell Lung Carcinoma 37Urinary Bladder Neoplasms 28Uterine Cervical Neoplasms 26Esophageal Neoplasms 25Colorectal Neoplasms 24Cholangiocarcinoma 24Biliary Tract Neoplasms 24Carcinoma 23Ovarian Neoplasms 21Carcinoma, Transitional Cell 18Carcinoma, Squamous Cell 17Recurrence 16Esophageal Squamous Cell Carcinoma 16Melanoma 13Breast Neoplasms 13Non-Squamous Non-Small Cell Lung Cancer 12Mesothelioma, Malignant 12Mesothelioma 12Nasopharyngeal Carcinoma 11Adenocarcinoma 11Gallbladder Neoplasms 10Endometrial Neoplasms 10

Interventions

motexafin gadolinium 1Talaporfin 1Rhenium 1Poly I-C 1Mitomycin 1Lomustine 1Folfox protocol 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Recurrence, Local × Cisplatin × Clear all
NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Sanofi

Phase 2/3 Completed
568 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Data powered by HemOnc (CC BY 4.0) Colophon âš¡